entinostat has been researched along with Carcinoma, Hepatocellular in 6 studies
Carcinoma, Hepatocellular: A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Herein, we describe the pharmacokinetic optimization of a series of class-selective histone deacetylase (HDAC) inhibitors and the subsequent identification of candidate predictive biomarkers of hepatocellular carcinoma (HCC) tumor response for our clinical lead using patient-derived HCC tumor xenograft models." | 1.38 | Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response. ( Cai, J; Chen, D; Chen, J; Chen, L; Chen, T; Feng, L; Guo, L; He, Y; Ji, Y; Jin, TG; Li, S; Liang, C; Lin, X; Liu, Y; Lu, X; Mei, J; Ning, Z; Pan, D; Pan, S; Peng, Z; Ren, S; Ren, Y; Rong, Y; Shan, S; She, J; Tang, G; Wang, Z; Wong, JC; Wu, X; Xu, C; Zhang, C; Zhang, M; Zhang, N; Zhang, W; Zhang, X; Zhang, Z; Zhao, R; Zhao, W; Zhou, M, 2012) |
| "Human hepatoma cell lines Hep3B and HepG2 as well as primary human foreskin fibroblasts as non-malignant controls were cultured under standardized conditions and incubated with increasing concentrations of CYC-202 and MS-275 as single agents and in combination." | 1.35 | The histone-deacetylase inhibitor MS-275 and the CDK-inhibitor CYC-202 promote anti-tumor effects in hepatoma cell lines. ( Gahr, S; Hahn, EG; Herold, C; Ocker, M; Peter, G; Wissniowski, TT, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wong, JC | 1 |
| Tang, G | 1 |
| Wu, X | 1 |
| Liang, C | 1 |
| Zhang, Z | 1 |
| Guo, L | 1 |
| Peng, Z | 1 |
| Zhang, W | 1 |
| Lin, X | 1 |
| Wang, Z | 1 |
| Mei, J | 1 |
| Chen, J | 1 |
| Pan, S | 1 |
| Zhang, N | 1 |
| Liu, Y | 1 |
| Zhou, M | 1 |
| Feng, L | 1 |
| Zhao, W | 1 |
| Li, S | 1 |
| Zhang, C | 2 |
| Zhang, M | 1 |
| Rong, Y | 1 |
| Jin, TG | 1 |
| Zhang, X | 2 |
| Ren, S | 1 |
| Ji, Y | 1 |
| Zhao, R | 1 |
| She, J | 1 |
| Ren, Y | 1 |
| Xu, C | 1 |
| Chen, D | 1 |
| Cai, J | 1 |
| Shan, S | 1 |
| Pan, D | 1 |
| Ning, Z | 1 |
| Lu, X | 1 |
| Chen, T | 1 |
| He, Y | 1 |
| Chen, L | 1 |
| Xiao, W | 1 |
| Dong, W | 1 |
| Saren, G | 1 |
| Geng, P | 1 |
| Zhao, H | 1 |
| Li, Q | 1 |
| Zhu, J | 1 |
| Li, G | 1 |
| Zhang, S | 1 |
| Ye, M | 2 |
| Gahr, S | 1 |
| Peter, G | 1 |
| Wissniowski, TT | 1 |
| Hahn, EG | 1 |
| Herold, C | 1 |
| Ocker, M | 1 |
| Lin, WH | 1 |
| Martin, JL | 1 |
| Marsh, DJ | 1 |
| Jack, MM | 1 |
| Baxter, RC | 1 |
| Li, QW | 1 |
| Xiao, WH | 1 |
| Sarengaowa, G | 1 |
| Dong, WW | 1 |
| Zhao, HX | 1 |
| Duan, XY | 1 |
| Zhu, JH | 1 |
| Kang, HR | 1 |
| Fu, Y | 1 |
| Hao, YX | 1 |
| Wang, RL | 1 |
| Song, LP | 1 |
| Wang, H | 1 |
| Guo, Y | 1 |
| Fu, M | 1 |
| Liang, X | 1 |
| Wang, R | 1 |
| Lin, C | 1 |
| Qian, H | 1 |
6 other studies available for entinostat and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.
Topics: Anilides; Animals; Biomarkers, Pharmacological; Carcinoma, Hepatocellular; Cell Line, Tumor; CpG Isl | 2012 |
Effects of the epigenetic drug MS-275 on the release and function of exosome-related immune molecules in hepatocellular carcinoma cells.
Topics: Benzamides; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Cytotoxicity, Immunolo | 2013 |
The histone-deacetylase inhibitor MS-275 and the CDK-inhibitor CYC-202 promote anti-tumor effects in hepatoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Carcinoma, Hepatocellular; Caspase | 2008 |
Involvement of insulin-like growth factor-binding protein-3 in the effects of histone deacetylase inhibitor MS-275 in hepatoma cells.
Topics: Acetylation; Adaptor Proteins, Signal Transducing; Benzamides; Carcinoma, Hepatocellular; Cell Cycle | 2011 |
[Histone deacetylase inhibitor MS-275 treatment alters immune molecule content and categories in hepatocarcinoma exosomes].
Topics: Antigens, Neoplasm; Benzamides; Carcinoma, Hepatocellular; Exosomes; Hep G2 Cells; Histocompatibilit | 2012 |
Antitumor activity of Chidamide in hepatocellular carcinoma cell lines.
Topics: Aminopyridines; Antineoplastic Agents; Apoptosis; Benzamides; Carcinoma, Hepatocellular; Cell Line, | 2012 |